Leukaemia Research Fund international research symposium on cytotoxic drug resistance in leukemia and other malignancies.
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001692:Biological Transport; D002945:Cisplatin / Q000494:pharmacology; D003226:Congresses as Topic; D003561:Cytarabine / Q000627:therapeutic use; D004247:DNA / Q000235:genetics; D004351:Drug Resistance; D005784:Gene Amplification; D005982:Glutathione Transferase / Q000502:physiology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D009705:Nucleosides / Q000378:metabolism; D010100:Oxygen / Q000378:metabolism; D010641:Phenotype; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009705:Nucleosides; D059005:Topoisomerase II Inhibitors; D003561:Cytarabine; D004247:DNA; D005982:Glutathione Transferase; D002945:Cisplatin; D010100:Oxygen